Refine
Has Fulltext
- yes (59)
Is part of the Bibliography
- yes (59)
Year of publication
Document Type
- Journal article (59)
Language
- English (59)
Keywords
- colorectal cancer (7)
- inflammatory bowel disease (3)
- CRC (2)
- Crohn's disease (2)
- Germany (2)
- Rectal cancer (2)
- antimicrobial stewardship (2)
- chemotherapy (2)
- complication (2)
- endoluminal (2)
- gastric cancer (2)
- gut barrier (2)
- ileocecal resection (2)
- inflammation (2)
- intestinal epithelial barrier (2)
- meta-analysis (2)
- metastasis (2)
- microbial spectrum (2)
- mortality (2)
- negative pressure (2)
- peritoneal carcinomatosis (2)
- surgery (2)
- surgical therapy (2)
- vacuum-assisted closure (2)
- 5-fluorouracil (1)
- Adrenocortical Carcinoma (1)
- BM (1)
- CA19-9 (1)
- COVID-19 (1)
- COVID-19 pandemic (1)
- CX5461 (1)
- Caco2 cells (1)
- Carcinomatosis (1)
- Chirurgie (1)
- Claudin2 (1)
- Crohn’s Disease (1)
- Crohn’s disease (1)
- Cushing (1)
- Dsg2 (1)
- EDS (1)
- Ehlers-Danlos syndrome (1)
- Epstein-Barr virus (1)
- FWGE (1)
- GDNF5 (1)
- GIST (1)
- Improved survival (1)
- KIT (1)
- Kono-S anastomosis (1)
- Krebs <Medizin> (1)
- LAMN (1)
- LND (1)
- LNE (1)
- Laparoscopy (1)
- Lymph nodes (1)
- MAPK pathway (1)
- MAPK signaling cascades (1)
- MIZ1 (1)
- MTL30 (1)
- MYC (1)
- Medizin (1)
- Minimally invasive surgery (1)
- Oncology (1)
- Organoids (1)
- PCI (1)
- PCR (1)
- PDGF (1)
- PI-3-kinase (1)
- PI3K/Akt/mTOR (1)
- POEM (1)
- Primary hyperparathyroidism (pHPT) (1)
- RET6 (1)
- RNAPOL1 (1)
- Radiochemotherapy (1)
- Roux-en-Y gastric bypass (1)
- SARS-CoV-2 (1)
- SSI (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- T cell receptors (1)
- T cells (1)
- TCR signaling cascade (1)
- TME (1)
- Time interval (1)
- V. saphena magna (1)
- Y-gastric bypass (1)
- ZfKD (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [99mTc]-Sestamibi scan (1)
- abdominal surgery (1)
- achalasia (1)
- adjuvant (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenocortical carcinoma (1)
- alternative splicing (1)
- anastomosis (1)
- anastomotic leak (1)
- anastomotic leakage (1)
- anorectal abscess (1)
- antibiotic prescribing quality (1)
- antibiotic prescription behavior (1)
- antibiotic resistance (1)
- anticoagulation (1)
- appendectomy (1)
- appendicitis (1)
- appendix (1)
- atrial fibrillation (1)
- autophagy (1)
- bariatric surgery (1)
- benzoquinone (1)
- biliopancreatic diversion (1)
- bladder (1)
- body weight (1)
- brain metastases (1)
- bridging (1)
- caco-2 cells (1)
- cancer (1)
- cancer cells (1)
- cancer diagnosis (1)
- cancer treatment (1)
- cancers and neoplasms (1)
- capture (1)
- carcinomas (1)
- case report (1)
- catheterization (1)
- catheters (1)
- cell cycle and cell division (1)
- cerebral metastases (1)
- chemistry (1)
- cholestasis (1)
- colon (1)
- colon cancer (1)
- colon resection (1)
- colorectal carcinoma (1)
- complications (1)
- conventional laparoscopic appendectomy (1)
- cost-effectiveness (1)
- cotransporter SGLT1 (1)
- curative resection (1)
- cytostatic (1)
- cytotoxicity (1)
- definition (1)
- desmosome (1)
- diagnosis (1)
- diagnostics (1)
- discharge definition (1)
- drug-eluting beads (1)
- duodenal jejunal bypass (1)
- elective surgery (1)
- endoscopic (1)
- enteric glial cells (1)
- enteric nervous system (1)
- enteroids (1)
- ephitelial cells (1)
- epidemiology (1)
- epidural block (1)
- epithelium (1)
- esophageal perforation (1)
- fish bone (1)
- fistulizing Crohn’s Disease (1)
- flow cytometry (1)
- focused surgical approach (1)
- food intake (1)
- foreign body ingestion (1)
- gastrointestinal infections (1)
- gastrointestinal perforation (1)
- gene regulation (1)
- geriatric (1)
- germline mutation (1)
- glucagon like peptide-1 (1)
- glucose metabolism (1)
- gut hormones (1)
- hepatic resection (1)
- hepatocellular carcinoma (1)
- imaging (1)
- inflammatory cell model (1)
- inguinal lymph node dissection (1)
- intercellular junctions (1)
- intestinal barrier (1)
- intestinal glucose (1)
- intestinal organoids (1)
- intraabdominal abscess (1)
- intragastric balloon (1)
- laparoscopic right colectomy (1)
- left hemicolectomy (1)
- liver resection (1)
- low-grade mucinous neoplasm (1)
- low-molecular heparin (1)
- low-risk intra-abdominal infections (1)
- lung resection (1)
- lymph node dissection (1)
- lymph nodes (1)
- lymphadenectomy (1)
- malignant melanoma (1)
- mastocytosis (1)
- measles virus (1)
- metachronous (1)
- multimodal (1)
- negative pressure wound therapy (1)
- neoadjuvant (1)
- neurotrophic factors (1)
- obesity (1)
- octogenarians (1)
- octogenerians (1)
- older adult (1)
- open wound treatment (1)
- operative (1)
- organoid (1)
- oxaliplatin (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic head cancer (1)
- parathyroid adenoma (1)
- patient-derived organoid (PDOs) (1)
- patient-derived tumor organoid (PDTO) (1)
- penetrating ileitis (1)
- perianal fistulas (1)
- perioperative antibiotic prophylaxis (1)
- perioperative chemotherapy (1)
- peroral endoscopic myotomy (1)
- platelet dysfunction (1)
- post-operative antibiotic treatment (1)
- postoperative bleeding (1)
- postoperative inflammation (1)
- preoperative localization (1)
- primary hyperparathyroidism (1)
- prognosis (1)
- prospective studies (1)
- protein expression (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- reactive oxygen species (1)
- rectum (1)
- recurrence survival (1)
- regional recurrence (1)
- repeat surgery (1)
- retrospective study (1)
- reverse transcriptase-polymerase chain reaction (1)
- review (1)
- ribosome (1)
- risk factor (1)
- risk factors (1)
- robotic surgery (1)
- screening (1)
- secondary skin closure (1)
- seminoma (1)
- single-port appendectomy (1)
- sleeve gastrectomy (1)
- small interferring RNA (1)
- super-obesity (1)
- superior (1)
- surgical (1)
- surgical and invasive medical procedures (1)
- surgical care (1)
- surgical intra-abdominal infections (1)
- surgical management (1)
- surgical oncology (1)
- surgical outcome (1)
- surgical procedures (1)
- surgical resection (1)
- surgical site infection (1)
- surgical site infections (1)
- survival (1)
- survival analysis (1)
- systematic review (1)
- terminal ileitis (1)
- thromboembolism (1)
- thyroid gland (1)
- thyroiditis (1)
- tight junction (1)
- transarterial chemoembolization (1)
- treatment (1)
- tumor disease (1)
- urinary tract infections (1)
- vascular type (1)
- vitamin D (1)
- wound infection (1)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (59)
- Theodor-Boveri-Institut für Biowissenschaften (21)
- Comprehensive Cancer Center Mainfranken (13)
- Medizinische Klinik und Poliklinik II (10)
- Medizinische Klinik und Poliklinik I (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Pathologisches Institut (4)
- Institut für Anatomie und Zellbiologie (3)
- Kinderklinik und Poliklinik (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 101042738 (1)
Colorectal cancer (CRC) is the third most common malignancy worldwide. Most patients with metastatic CRC develop liver or lung metastases, while a minority suffer from brain metastases. There is little information available regarding the presentation, treatment, and overall survival of brain metastases (BM) from CRC. This systematic review and meta-analysis includes data collected from three major databases (PubMed, Cochrane, and Embase) based on the key words “brain”, “metastas*”, “tumor”, “colorectal”, “cancer”, and “malignancy”. In total, 1318 articles were identified in the search and 86 studies matched the inclusion criteria. The incidence of BM varied between 0.1% and 11.5%. Most patients developed metastases at other sites prior to developing BM. Lung metastases and KRAS mutations were described as risk factors for additional BM. Patients with BM suffered from various symptoms, but up to 96.8% of BM patients were asymptomatic at the time of BM diagnosis. Median survival time ranged from 2 to 9.6 months, and overall survival (OS) increased up to 41.1 months in patients on a multimodal therapy regimen. Several factors including age, blood levels of carcinoembryonic antigen (CEA), multiple metastases sites, number of brain lesions, and presence of the KRAS mutation were predictors of OS. For BM diagnosis, MRI was considered to be state of the art. Treatment consisted of a combination of surgery, radiation, or systemic treatment.
Background
International consensus criteria (ICC) have redefined borderline resectability for pancreatic ductal adenocarcinoma (PDAC) according to three dimensions: anatomical (BR-A), biological (BR-B), and conditional (BR-C). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumour and vessels but that biological and conditional dimensions also are important.
Methods
Patients’ tumours were retrospectively defined borderline resectable according to ICC. The study cohort was grouped into either BR-A or BR-B and compared with patients considered primarily resectable (R). Differences in postoperative complications, pathological reports, overall (OS), and disease-free survival were assessed.
Results
A total of 345 patients underwent resection for PDAC. By applying ICC in routine preoperative assessment, 30 patients were classified as stage BR-A and 62 patients as stage BR-B. In total, 253 patients were considered R. The cohort did not contain BR-C patients. No differences in postoperative complications were detected. Median OS was significantly shorter in BR-A (15 months) and BR-B (12 months) compared with R (20 months) patients (BR-A vs. R: p = 0.09 and BR-B vs. R: p < 0.001). CA19-9, as the determining factor of BR-B patients, turned out to be an independent prognostic risk factor for OS.
Conclusions
Preoperative staging defining surgical resectability in PDAC according to ICC is crucial for patient survival. Patients with PDAC BR-B should be considered for multimodal neoadjuvant therapy even if considered anatomically resectable.
Purpose
Traditionally, previous wound infection was considered a contraindication to secondary skin closure; however, several case reports describe successful secondary wound closure of wounds "preconditioned" with negative pressure wound therapy (NPWT). Although this has been increasingly applied in daily practice, a systematic analysis of its feasibility has not been published thus far. The aim of this study was to evaluate secondary skin closure in previously infected abdominal wounds following treatment with NPWT.
Methods
Single-center retrospective analysis of patients with infected abdominal wounds treated with NPWT followed by either secondary skin closure referenced to a group receiving open wound therapy. Endpoints were wound closure rate, wound complications (such as recurrent infection or hernia), and perioperative data (such as duration of NPWT or hospitalization parameters).
Results
One hundred ninety-eight patients during 2013-2016 received a secondary skin closure after NPWT and were analyzed and referenced to 67 patients in the same period with open wound treatment after NPWT. No significant difference in BMI, chronic immunosuppressive medication, or tobacco use was found between both groups. The mean duration of hospital stay was 30 days with a comparable duration in both patient groups (29 versus 33 days, p = 0.35). Interestingly, only 7.7% of patients after secondary skin closure developed recurrent surgical site infection and in over 80% of patients were discharged with closed wounds requiring only minimal outpatient wound care.
Conclusion
Surgical skin closure following NPWT of infected abdominal wounds is a good and safe alternative to open wound treatment. It prevents lengthy outpatient wound therapy and is expected to result in a higher quality of life for patients and reduce health care costs.
Background
Patients with coronavirus disease 2019 (COVID-19) who undergo surgery have impaired postoperative outcomes and increased mortality. Consequently, elective and semi-urgent operations on the increasing number of patients severely affected by COVID-19 have been indefinitely postponed.in many countries with unclear implications on disease progression and overall survival. The purpose of this study was to evaluate whether the establishment of a standardized screening program for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sufficient to ensure high-quality medical and surgical treatment of COVID-19 and non-COVID-19 patients while minimizing in-hospital SARS-CoV-2 transmission.
Methods
The screening program comprised polymerase chain reaction (PCR) testing of nasopharyngeal swabs and a standardized questionnaire about potential symptoms for SARS-CoV-2 infection. All elective and emergency patients admitted to the surgical department of a tertiary-care hospital center in Lower Franconia, Germany, between March and May 2020 were included and their characteristics were recorded.
Results
Out of the study population (n = 657), 509 patients (77.5%) had at least one risk factor for a potentially severe course of COVID-19 and 164 patients (25%) were active smokers. The average 7-day incidence in Lower Franconia was 24.0/100,000 during the observation period. Preoperative PCR testing revealed four asymptomatic positive patients out of the 657 tested patients. No postoperative SARS-CoV-2 infection or transmission could be detected.
Conclusion
The implementation of a standardized preoperative screening program to both COVID-19 and non-COVID-19 patients can ensure high-quality surgical care while minimizing infection risk for healthcare workers and potential in-hospital transmission.
Epstein-Barr virus (EBV) is best known for infection of B cells, in which it usually establishes an asymptomatic lifelong infection, but is also associated with the development of multiple B cell lymphomas. EBV also infects epithelial cells and is associated with all cases of undifferentiated nasopharyngeal carcinoma (NPC). EBV is etiologically linked with at least 8% of gastric cancer (EBVaGC) that comprises a genetically and epigenetically distinct subset of GC. Although we have a very good understanding of B cell entry and lymphomagenesis, the sequence of events leading to EBVaGC remains poorly understood. Recently, ephrin receptor A2 (EPHA2) was proposed as the epithelial cell receptor on human cancer cell lines. Although we confirm some of these results, we demonstrate that EBV does not infect healthy adult stem cell-derived gastric organoids. In matched pairs of normal and cancer-derived organoids from the same patient, EBV only reproducibly infected the cancer organoids. While there was no clear pattern of differential expression between normal and cancer organoids for EPHA2 at the RNA and protein level, the subcellular location of the protein differed markedly. Confocal microscopy showed EPHA2 localization at the cell-cell junctions in primary cells, but not in cancer cell lines. Furthermore, histologic analysis of patient tissue revealed the absence of EBV in healthy epithelium and presence of EBV in epithelial cells from inflamed tissue. These data suggest that the EPHA2 receptor is not accessible to EBV on healthy gastric epithelial cells with intact cell-cell contacts, but either this or another, yet to be identified receptor may become accessible following cellular changes induced by inflammation or transformation, rendering changes in the cellular architecture an essential prerequisite to EBV infection.
Perianal fistulizing Crohn’s Disease (CD) with abscess formation represents an aggressive phenotype in Inflammatory Bowel Disease (IBD) with increased morbidity. Treatment is multidisciplinary and includes antibiotics, but knowledge about the microbial spectrum is rare often resulting in inadequate antimicrobial therapy. In this single center retrospective study, all patients who were operated due to perianal abscess formation were retrospectively analyzed and the microbial spectrum evaluated. Patients were divided into a CD and non-CD group with further subgroup analysis. 138 patients were finally included in the analysis with 62 patients suffering from CD. Relevant differences were detected for the microbial spectrum with anaerobic bacteria being significantly more often isolated from non-CD patients. In a subgroup-analysis of CD patients only, medical therapy had a relevant effect on the microbial spectrum since Streptococcus groups and Enterobacterales were significantly more often isolated in patients treated with steroids compared to those being treated by antibodies. In conclusion, the microbial spectrum of patients suffering from CD varies significantly from non-CD patients and immunosuppressive medication has a relevant effect on isolated pathogens. Based on that, adaption of antibiotic treatment might be discussed in the future.
Background:
The treatment strategies for colorectal cancer located in the right side of the colon have changed dramatically during the last decade. Due to the introduction of complete mesocolic excision (CME) with central ligation of the vessels and systematic lymph node dissection, the long-term survival of affected patients has increased significantly. It has also been proposed that right-sided colon resection can be performed laparoscopically with the same extent of resection and equal long-term results.
Methods:
A retrospective evaluation of a prospectively expanded database on right-sided colorectal cancer or adenoma treated at the University Hospital of Wuerzburg between 2009 and 2016 was performed. All patients underwent CME. This data was analyzed alone and in comparison to the published data describing laparoscopic right-sided colon resection for colon cancer.
Results:
The database contains 279 patients, who underwent right-sided colon resection due to colorectal cancer or colorectal adenoma (255 open; 24 laparoscopic). Operation data (time, length of stay, time on ICU) was equal or superior to laparoscopy, which is comparable to the published results. Surprisingly, the surrogate parameter for correct CME (the number of removed lymph nodes) was significantly higher in the open group. In a subgroup analysis only including patients who were feasible for laparoscopic resection and had been operated with an open procedure by an experienced surgeon, operation time was significantly shorter and the number of removed lymph nodes is significantly higher in the open group.
Conclusion:
So far, several studies demonstrate that laparoscopic right-sided colon resection is comparable to open resection. Our data suggests that a consequent CME during an open operation leads to significantly more removed lymph nodes than in laparoscopically resected patients and in several so far published data of open control groups from Europe. Further prospective randomized trials comparing the long-term outcome are urgently needed before laparoscopy for right-sided colon resection can be recommended ubiquitously.
Simple Summary
Despite significant strides in multimodal therapy, cancers still rank within the first three causes of death especially in industrial nations. A lack of individualized approaches and accurate preclinical models are amongst the major barriers that limit the development of novel therapeutic options and drugs. Recently, the 3D culture system of organoids was developed which stably retains the genetic and phenotypic characteristics of the original tissue, healthy as well as diseased. In this review, we summarize current data and evidence on the relevance and reliability of such organoid culture systems in cancer research, focusing on their role in drug investigations (in a personalized manner).
Abstract
Organoids are a new 3D ex vivo culture system that have been applied in various fields of biomedical research. First isolated from the murine small intestine, they have since been established from a wide range of organs and tissues, both in healthy and diseased states. Organoids genetically, functionally and phenotypically retain the characteristics of their tissue of origin even after multiple passages, making them a valuable tool in studying various physiologic and pathophysiologic processes. The finding that organoids can also be established from tumor tissue or can be engineered to recapitulate tumor tissue has dramatically increased their use in cancer research. In this review, we discuss the potential of organoids to close the gap between preclinical in vitro and in vivo models as well as clinical trials in cancer research focusing on drug investigation and development.
Background:
Inguinal lymph node dissection (LND) is a surgical procedure with a high morbidity rate. Variations in surgical procedure, such as sparing of the saphenous vein, have been proposed to reduce surgical morbidity. While sparing of the saphenous vein has shown promising results in earlier studies, data for this procedure in melanoma patients are rare. In this retrospective study, we report 10-year findings on the effects of saphenous vein-sparing LND on surgical morbidity and oncologic outcomes in melanoma patients.
Methods:
A retrospective analysis of melanoma patients receiving inguinal LND in our facility between 2003 and 2013 was performed. Patients were divided into two groups: the saphenous vein resection group and the vein sparing group. Surgical morbidity, including wound infection, lymphatic fistula, severe bleeding, neurological complications, and chronic lymphedema, as well as regional recurrence-free survival were investigated.
Results:
A total of 106 patients were included in this study; of these, the saphenous vein was spared in 41 patients (38.7%). The rate of lymphatic fistula was 51.6 vs. 48.8%, wound infection occurred in 31.3 vs. 24.4%, and patients suffered from chronic lymphedema in 30.0 vs. 26.5% in V. saphena magna resection vs. sparing group. Differences observed, however, were not significant. No difference in regional recurrence-free survival between the two study groups was detected.
Conclusions:
The results of our retrospective analysis could not confirm the promising results reported in earlier studies. Thus, sparing of the saphenous vein appears to be optional.
Familial gastrointestinal stromal tumors (GIST) are dominant genetic disorders that are caused by germline mutations of the type III receptor tyrosine kinase KIT. While sporadic mutations are frequently found in mastocytosis and GISTs, germline mutations of KIT have only been described in 39 families until now. We detected a novel germline mutation of KIT in exon 11 (p.Lys-558-Asn; K558N) in a patient from a kindred with several GISTs harboring different secondary somatic KIT mutations. Structural analysis suggests that the primary germline mutation alone is not sufficient to release the autoinhibitory region of KIT located in the transmembrane domain. Instead, the KIT kinase module becomes constitutively activated when K558N combines with different secondary somatic mutations. The identical germline mutation in combination with an additional somatic KIT mutation was detected in a second patient of the kindred with seminoma while a third patient within the family had a cutaneous mastocytosis. These findings suggest that the K558N mutation interferes with the juxtamembranous part of KIT, since seminoma and mastocystosis are usually not associated with exon 11 mutations.